Skip Navigation


JAC Advance Access originally published online on December 19, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/2/403-b    most recent
dkh054v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cynamon, M. H.
Right arrow Articles by Yeo, A. E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cynamon, M. H.
Right arrow Articles by Yeo, A. E. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 403-405
© 2004 The British Society for Antimicrobial Chemotherapy

Correspondence

BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis

Michael H. Cynamon1,*, Enriques Alvirez-Freites1 and Anthony E. T. Yeo2

1 Department of Medicine, Veterans Affairs Medical Center, 800 Irving Avenue, Syracuse, NY 13210; 2 Jacobus Pharmaceutical Company, Princeton, NJ, USA

Keywords: BB-3497, peptide deformylase inhibitors, TB

The first 10% of the full text of this article appears below.

Sir,

Bacterial peptide deformylase (PDF) belongs to a subfamily of metalloproteases catalysing the removal of the N-terminal formyl group from newly synthesized proteins. PDF is essential in prokaryotes and appears to be conserved throughout the eubacteria. Thus, it may be suitable as a target for new chemotherapeutic agents. Various PDF inhibitors have in vitro activities against several pathogens including Escherichia coli, Haemophilus influenzae and Staphylococcus aureus.1–3 In view of their wide spectrum of activity, six PDF inhibitors were initially screened against . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?